Preview

Научно-практическая ревматология

Расширенный поиск

Остеопороз и венозный тромбоэмболизм

https://doi.org/10.14412/1995-4484-2011-868

Полный текст:

Список литературы

1. <div><p>Access Economics. The burden of venous thromboembolism in Australia. Report for the Australia and New Zealand Working Party on the Management and Prevention of Venous Thromboembolism 2008; 49 p. http://www.accesseconomics.com.au/publicationsreports/showreport.php?id=161</p><p>White R.H. The epidemiology of venous thromboembolism. Circulation 2003; 107(23, Suppl. 1): 14-8.</p><p>Nordstrom M., Lindblad B., Bergqvist D., Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.</p><p>Anderson F.A., Wheeler H.B., Goldberg R.J. et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991; 151: 933-8.</p><p>Oger E. Incidence of venous thromboembolism: a community-based study in western France. Thromb Haemost 2000; 83: 657-60.</p><p>Cushman M., Tsai A.W., White R.H. et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19-25.</p><p>Naess I.A., Christiansen S.C., Romundstad P. et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 692-9.</p><p>Goldhaber S.Z. Pulmonary embolism. Lancet 2004; 363(9417): 1295-305.</p><p>Cushman M. Epidemiology and Risk Factors for Venous Thrombosis. Semin Hematol 2007; 44(2): 62-9.</p><p>Heit J.A., Silverstein M.D., Mohr D.N. et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 1999; 159: 445-53.</p><p>Респираторная медицина. Руководство. Под ред. академика РАМН А.Г. Чучалина. М.: ГЭОТАР- Медиа, 2007; 2: 81.</p><p>Anderson F.A. Jr., Spencer F.A. Risk factors for venous thromboembolism. Circulation; 2003; 107(23, Suppl. 1): I-9- I-16.</p><p>Blann A.D., Lip G.Y. Venous thromboembolism. Brit Med J 2006; 332(7535): 215-9.</p><p>Sare G.M., Gray L.J., Bath P.M.W. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008; 29(16): 2031-41.</p><p>Canonico M., Plu-Bureau G., Lowe G.D., Scarabin P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. Brit Med J 2008; 336(7655): 1227-31.</p><p>Farquhar C.M., Marjoribanks J., Lethaby A. et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005; 20(3): CD004143.</p><p>Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. Под ред. О.М. Лесняк, Л.И. Беневоленской. М.: ГЭОТАР-Медиа, 2009; 145 с.</p><p>Cauley J.A., Norton L., Lippman M.E. et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65(2): 125-34.</p><p>Adomaityte J., Farooq M., Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 2008; 99(2): 338-42.</p><p>O'Donnell S., Cranney A., Wells G.A. et al. Strontium ranelate for preventing and treating postmenopausal osteoposis. Cochrane Database Systematic Review 2006(4): CD005326.</p><p>Servier Laboratories Limited. Protelos: summary of product characteristics. Servier, 2008 Jan 23 [on-line]. Available from URL: http://www.medicines.org.uk/EMC/medicine/15410/SPC/Protelos/ [Accessed 2010 May 12].</p><p>Jick H., Derby L.E., Wald Myers M. et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3.</p><p>Cummings S.R., Eckert S., Krueger K.A. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189-97.</p><p>Vickers M.R., MacLennan A.H., Lawton B. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. Brit Med J 2007; 335: 239.</p><p>Barrett-Connor E., Mosca L., Collins P. et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37.</p><p>Halil M., Cankurtaran M., Yavuz B.B. et al. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann Pharmacother 2007; 41(1): 41-5.</p><p>Grosso A., Douglas I., Hingorani A. et al. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Brit J Clin Pharmacol 2008; 66(5): 689-94.</p><p>Osborne V., Layton D., Perrio M. et al. Incidence of venous thromboembolism in users of strontium ranelate. An analysis of data from a prescription-event monitoring study in England. Drug Saf 2010; 33(7): 579-91.</p><p>Breart G., Cooper C., Meyer O. et al. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int 2009; 21(7): 1181-7.</p><p>Brown J.P., Josse R.G. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002; 167(Suppl. 10): 1-34.</p><p>Naess I.A., Christiansen S.C., Romundstad P. et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 692-9.</p><p>Silverstein M.D., Heit J.A., Mohr D.N. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25- year population-based study. Arch Intern Med 1998; 158: 585-93.</p><p>Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-60.</p><p>Vestergaard P., Schwartz K., Pinholt E. M. et al. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. 2009 [Epub. ahead of print].</p><p>Sevitt S., Gallagher N.G. Prevention of venous thrombosis and pulmonary embolism in injured patients: a trial of anticoagulant prophylaxis with phenindione in middle aged and elderly patients with fractured necks or femurs. Lancet 1959; ii: 981-9.</p><p>Lutsey P.L., Virnig B.A., Durham S.B. et al. Correlates and consequences of venous thromboembolism: The Iowa Women's Health Study. Am J Public Health 2009; Nov 12 [Epub. ahead of print].</p><p>Pottier P., Hardouin J.B., Lejeune S. et al. Immobilization and the risk of venous thromboembolism. A meta-analysis on epidemiological studies. Thromb Res 2009; 124(4): 468-76.</p><p>Rosendaal F.R., van Hylckama Vlieg A., Doggen C.J. Venous thrombosis in the elderly. J Thromb Haemost 2007; 5(Suppl. 1): 310-7.</p><p>Carson J.L., Kelley M.A., Duff A. et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326; 1240-5.</p><p>Bannink L., Doggen C.J.M., Nelissen R.G.H.H., Rosendaal F.R. Increased risk of venous thrombosis after orthopedic and general surgery: results of the MEGA study (abstract). J Thromb Haemost 2005; 3(Suppl. 1): 1653.</p><p>Eikelboom J.W., Quinlan D.J., Douketis J.D. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358: 9-15.</p><p>McNamara I., Sharma A., Prevost T., Parker M. Symptomatic venous thromboembolism following a hip fracture. Acta Orthop 2009; 80(6): 687-92.</p><p>Samama M.M. Epidemiology of risk factors of deep venous thrombosis (DVT) of the lower limbs in community practice: the SIRIUS study. Thromb Haemost 1993; 69: 763.</p><p>Hotoleanu C., Porojan-Iuga M., Rusu M.L., Andercou A. Hyperhomocysteinemia: clinical and therapeutical involvement in venous thrombosis. Rom J Intern Med 2007; 45(2): 159-64.</p><p>Gjesdal C.G., Vollset S.E., Ueland P.M. et al. Plasma homocysteine, folate, and vitamin B12 and the risk of hip fracture: the hordaland homocysteine study. J Bone Miner Res 2007; 22(5): 747-56.</p></div><br />


Для цитирования:


Баранова И.А., Баранова И.А. Остеопороз и венозный тромбоэмболизм. Научно-практическая ревматология. 2011;49(1):58-61. https://doi.org/10.14412/1995-4484-2011-868

For citation:


Baranova I.A., Baranova I.A. Osteoporosis and venous thromboembolism. Rheumatology Science and Practice. 2011;49(1):58-61. (In Russ.) https://doi.org/10.14412/1995-4484-2011-868

Просмотров: 685


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)